Anthropic has quietly established a physical wet biology laboratory in the San Francisco Bay Area, marking a major transition from computer-based modeling to real-world experimentation. Led by Eric Kauderer-Abrams, the initiative aims to use Claude AI to automate robotic lab work and accelerate treatments for rare diseases. However, the move sparks intense industry debate, coming alongside warnings from Anthropic's own researchers about existential AI risks and bioterrorism.
Anthropic wet biology lab operations
- ▪An Anthropic spokesperson clarified that the wet biology laboratory is focused on fundamental biology rather than drug discovery specifically
- ▪Anthropic's head of life sciences, Eric Kauderer-Abrams, confirmed that the company conducts real lab work in its own facilities and with external partners
- ▪Anthropic has established a physical wet biology laboratory in the San Francisco Bay Area to conduct physical experiments
AI-driven drug discovery ambitions
- ▪Anthropic is focusing its drug development efforts on preclinical work for rare and neglected diseases that the traditional pharmaceutical industry finds financially unattractive
- ▪Anthropic CEO Dario Amodei stated in an essay that AI could cure most major diseases in the next 5 to 10 years
- ▪Anthropic is avoiding clinical trials to prevent direct competition with its pharmaceutical customers, which include Genentech, Bristol Myers Squibb, and Novo Nordisk
Claude AI laboratory automation
- ▪Anthropic aims to use its Claude AI model to direct robotic units to execute science experiments with limited human intervention
- ▪Anthropic launched the Model Hardware Standard in August 2026 to help artificial intelligence systems operate laboratory equipment
AI bioterrorism safety concerns
- ▪Anthropic researcher Jacob Coxon resigned and warned that AI developers believe the technology could kill humanity by the end of the decade
- ▪Anthropic CEO Dario Amodei called for an industry development slowdown and self-regulation, citing bioterrorism as one of the biggest risks of AI
Anthropic life sciences expansion strategy
- ▪Anthropic acquired the stealth AI biotechnology startup Coefficient Bio in April 2026 to help build tools for drug development
- ▪Anthropic launched a Life Sciences Verification Program in September 2026 to grant vetted biology researchers access to its most powerful AI models
- ▪Anthropic appointed Novartis CEO Vas Narasimhan to its board of directors prior to September 2026
Debatable claims
- ▪AI will cure most major diseases within the next decade
- ▪AI systems should not conduct physical biology experiments without direct human oversight
Story comments
Loading comments…